

















cc-by-nc (c) Wolters Kluwer Health, 2018 
Molecular classification of grade 3 endometrioid endometrial 
cancers identifies distinct prognostic subgroups
Tjalling Bosse, MD1, Remi A. Nout, MD1, Jessica N. McAlpine, MD2, Melissa K. McConechy, 
MD3, Heidi Britton, MD3, Yaser Hussein, MD4, Carlene Gonzalez, BA4, Raji Ganesan, MD5, 
Jane C. Steele, MD5, Beth T. Harrison, MD6, Esther Oliva, MD6, August Vidal, MD7, Xavier 
Matias-Guiu, MD7, Nadeem R. Abu-Rustum, MD8, Douglas A. Levine, MD8,*, C. Blake Gilks, 
MD3, and Robert A. Soslow, MD4
1Departments of Pathology and Radiation Oncology, Leiden University Medical Center, The 
Netherlands 2Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, 
University of British Columbia, Vancouver, BC, Canada 3Department of Pathology and Laboratory 
Medicine, University of British Columbia and BC Cancer Agency, Vancouver, BC, Canada 
4Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA 
5Birmingham Women’s HS Foundation Trust, Birmingham, UK 6Department of Pathology, 
Massachusetts General Hospital, Boston, MA, USA 7Department of Pathology, Hospital U Arnau 
de Vilanova and Hospital U de Bellvitge, Universities of Lleida and Barcelona, IDIBELL, 
IRBLLEIDA, CIBERONC, Spain 8Department of Surgery, Memorial Sloan Kettering Cancer 
Center, New York, NY, USA
Abstract
Our aim was to investigate whether molecular classification can be used to refine prognosis in 
grade 3 endometrioid endometrial carcinomas (EECs). Grade 3 EECs were classified into four 
subgroups: p53-abnormal, based on mutant-like immunostaining (p53abn); MMR-deficient, based 
on loss of mismatch repair protein expression (MMRd); presence of POLE exonuclease domain 
hotspot mutation (POLE); no specific molecular profile (NSMP), in which none of these 
aberrations were present. Overall (OS), and recurrence-free survival (RFS) rates were compared 
using the Kaplan-Meier method (Log-Rank test) and univariable and multivariable Cox 
proportional hazard models. In total, 381 patients were included. The median age was 66 years 
(range 33–96). FIGO stages (2009) were as follows: IA, 171 (44.9%), IB, 120 (31.5%), II, 24 
(6.3%), III, 50 (13.1%), IV, 11 (2.9%). There were 49 (12.9%) POLE, 79 (20.7%) p53abn, 115 
(30.2%) NSMP, and 138 (36.2%) MMRd tumors. Median follow-up of patients was 6.1 years 
(range 0.2–17.0). Compared to patients with NSMP, patients with POLE mutant grade 3 EEC (OS: 
Hazard Ratio [HR] 0.36 [95%CI: 0.18–0.70], p=0.003; RFS: HR 0.17 [0.05–0.54], p=0.003) had a 
significantly better prognosis; patients with p53abn tumors had a significantly worse RFS (HR 
1.73 [1.09–2.74], p0.021); patients with MMRd tumors showed a trend towards better RFS. 
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Estimated 5-year OS rates were as follows: POLE 89%, MMRd 75%, NSMP 69%, p53abn 55% 
(Log Rank p=0.001). Five-year RFS rates were as follows: POLE 96%, MMRd 77%, NSMP 64%, 
p53abn 47% (p=0.000001), respectively. In a multivariable Cox model that included age and FIGO 
stage, POLE and MMRd status remained independent prognostic factors for better RFS; p53 status 
was an independent prognostic factor for worse RFS. Molecular classification of grade 3 EECs 
reveals that these tumors are a mixture of molecular subtypes of endometrial carcinoma, rather 
than a homogeneous group. The addition of molecular markers identifies prognostic subgroups, 
with potential therapeutic implications.
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Introduction
Endometrial cancer is a heterogenous disease, with an overall 5-year survival rate of 
approximately 80%.1 There is a critical need to improve the identification of early-stage 
patients who may benefit from adjuvant therapy, and to identify patients with metastatic 
disease for whom a specific targeted therapy may be advantageous. To facilitate this, 
clinicopathologic variables are incorporated into the current risk assessment. For example, 
Stage I/grade 3 endometrioid-type endometrial cancers (EECs) are considered to pose a 
higher risk of recurrence; therefore, adjuvant radiotherapy is administered in many centers to 
treat these tumors. Recent molecular profiling has provided novel insight into the molecular 
heterogeneity of endometrial cancer.
Studies documenting molecular heterogeneity in endometrial cancer using genome-wide 
analyses, particularly those from the Cancer Genome Atlas (TCGA), have identified four 
distinct molecular subclasses based on genomic architecture/mutational burden.2 These 
include the ultramutated subtype, defined by mutation in the exonuclease domain of DNA 
Polymerase epsilon (POLE); the hypermutated, microsatellite-unstable subclass, with 
deficiency of one or more mismatch repair proteins (MMRd); the copy number-high 
subtype, which is characterized by mutations in p53; and the copy number-low subtype that 
does not have a surrogate marker. More recently, clinically applicable methodologies have 
been applied to identify these groups. These methodologies may also impact prognosis and 
identify potentially targetable underlying molecular abnormalities.3–8 With the use of 
immunohistochemistry (IHC) and targeted sequencing of POLE, this approach becomes 
cost-effective and may be rapidly implemented in current practice. Recent studies have 
independently proven this concept using clinical trials materials4,5 and unselected cases 
drawn from multiple institutions.7 The Institute of Medicine guidelines for development of 
“omics-based” biomarkers were followed in the latter study.9
In the current study, we focused our efforts on grade 3 EECs. These tumors comprise a 
subset of endometrial carcinoma that has engendered significant controversy with respect to 
pathogenesis (type I or type II?), prognosis (comparable to that of serous carcinoma, or more 
favorable?), and treatment. Diagnosis is associated with significant interobserver variability 
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and suboptimal reproducibility. Furthermore, this is the only tumor type represented in each 
of the four genomic subgroups of the TCGA cohort. We tested the hypothesis that the 
molecular subtypes of grade 3 EECs are associated with significant differences in prognosis, 
using a clinically applicable molecular classification tool in a large, well-characterized 
cohort of grade 3 EECs from 6 centers in North America and Europe.
Methods
Institutional approval for this study was obtained from each of the participating centers.
FIGO grade 3 EECs with clinical follow-up data were collected from 6 institutions in 
Europe and North America (Table 1). Strict diagnostic criteria were applied, as follows: 1) 
tumors demonstrated endometrioid lineage evidenced by a component of low-grade 
endometrioid adenocarcinoma with low-intermediate nuclear grade and/or metaplasias 
typical of endometrioid differentiation, with exclusion of histological mimics (i.e. 
“confirmatory endometrioid features”); 2) tumors were characterized by predominantly solid 
architecture exclusive of squamous differentiation, or mixtures of glandular and solid 
architecture with diffusely distributed high-grade nuclei (Figure 1).
Molecular subgroup assignment
POLE sequencing for hotspots in the exonuclease domain (exons 9–14) was performed 
using either Sanger or next-generation approaches, as described previously.4,7 Either 2 
(PMS2 and MSH6) or 4 (MLH1, PMS2, MSH2, MSH6) DNA mismatch repair IHC markers 
were performed on representative sections at the referring institution, as well as p53 IHC 
staining (Figure 1). DNA mismatch repair results were scored as abnormal if no tumor 
nuclear staining was found in the presence of an intact internal control. Mutation-type p53 
staining was recognized either by overexpression (intense staining of >75% tumor cell 
nuclei) or no expression in tumor cell nuclei, in the presence of an intact internal control. In 
a subset of cases, sequencing was performed on tumors with ambiguous p53 IHC results. 
Participating institutions used slightly different approaches, the details of which are 
described in the Supplemental Methodology.
Assignation of carcinomas to TCGA-like subgroups (genomic subgroup classification) 
resulted in the following categories:
POLE mutation (POLE)—pathogenic variants in the exonuclease domain of DNA 
Polymerase epsilon, which were characterized by the TCGA as “ultramutated” (in the 
absence of MMRd or abnormal p53 expression).
Mismatch repair deficient (MMRd)—abnormal expression of one or more mismatch 
repair proteins by IHC, which is highly concordant with MSI-H status and assignment to the 
TCGA “hypermutated” group (in the absence of POLE mutation or abnormal p53 
expression).10,11
p53 abnormal (p53abn)—exhibiting aberrant p53 immunostaining (IHC score 0 for 
complete absence of protein expression, as in null mutations or overexpression, defined as 
Bosse et al. Page 3













intense staining of >75% of tumor cell nuclei) in the absence of POLE mutations or MMRd. 
This group largely corresponds to the “copy number-high/serous-like” TCGA group.
No specific molecular profile (NSMP)—exhibiting normal p53 and MMR expression by 
IHC and no mutations in the exonuclease domain of POLE, analogous to the “copy number-
low” subgroup in the TCGA.
Cases that could not be assigned to any of the above categories—either because one or more 
assays failed (incomplete profile) or because more than one classifier was present (e.g. 
POLE and p53abn)—were excluded from this study.
Clinical data were obtained by review of medical records, and appropriate statistical tests 
(Log-rank for OS and RFS [Kaplan-Meier] and Cox proportional hazards modeling for uni- 
and multivariable analyses) were performed to investigate the clinical significance of the 
molecular classification. FIGO stages (2009) were grouped for statistical analysis, providing 
alignment with most clinical algorithms, as follows: Stage IA, Stage IB, and Stages II–IV.
As we anticipated that a significant percentage of the FIGO grade 3 EECs would map to the 
p53abn category, we collected staging data from the Memorial Sloan Kettering Cancer 
Center database on endometrial serous carcinoma patients who were surgically staged 
(n=409). The aim was to detect differences in stage distribution by comparing the p53abn 
endometrioid category with serous carcinomas, tumors that were clustered together in the 
TCGA study.2
Results
Three hundred and eighty-one patients met the inclusion criteria. Median follow-up was 6.1 
years (range 0.2–17.0). Median age was 66 years (range 33–96). The FIGO 2009 stage 
distribution was as follows: IA, 44.9%; IB, 31.5%; II, 6.3%; III, 13.1%; IV, 2.9%.
Genomic subgroup classification and demographics
The classification tool yielded the following distribution of subgoups: POLE—12.9%; 
MMRd—36.2%; p53abn—20.7%; NSMP—30.2%. Table 2 shows the distribution of 
genomic subgroups stratified by stage. An overwhelming majority of POLE mutant 
carcinomas were Stage I (47/48, 98%), in contrast to other types (p=0.0003). MMRd and 
NSMP carcinomas were relatively evenly distributed in Stages I–IV. The majority (44/79, 
56%) of p53abn carcinomas were Stage IA, with only 22% (17/79) in Stages II–IV. Of note, 
MMRd tumors comprised a relatively large proportion of Stages II–IV (41/85, 48%). 
Median age also varied in relation to genomic subgroup, with POLE mutant carcinoma 
patients being youngest (median age 60 years, p=0.00006). Patients with tumors in the three 
other categories presented at nearly identical median ages (65–69 years).
Stage comparison: p53abn FIGO grade 3 endometrioid versus serous carcinoma
As stated above, 22% of patients with p53abn grade 3 EECs presented at Stages II–IV. This 
stands in contrast to the institutional series of surgically staged serous carcinoma patients, of 
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whom 58.36% presented at Stages II–IV (p<0.0001). Presentation at Stages IIIC (17.76%) 
and IVB (22.65%) was notable.
Outcomes analyses
Table 3 shows the relationships between stage and clinical outcomes, and age and clinical 
outcomes. Stage was independently associated with OS and RFS, whereas age was 
independently associated only with OS. Compared to outcomes in Stage IA tumors, Stage IB 
tumors had a hazard ratio (HR) of 1.64 (confidence interval [CI]: 1.00–2.69) for RFS 
(p=0.059); Stage II–IV tumors had HRs of 3.73 (CI: 2.54–5.49) and 4.55 (CI: 2.83–7.33) for 
OS and RFS, respectively (p<0.001 for both) (Figure 2).
Genomic subgroup classification was independently associated with RFS (Table 4). Patients 
with POLE mutant carcinomas had significantly better RFS, compared to patients with 
NSMP tumors (HR=0.23, 0.07–0.77) p=0.017. The MMRd group showed a trend towards 
better RFS, compared to the NSMP group (HR=0.61, 0.37–1.00 CI, p=0.052). RFS in 
patients with p53abn cancers was unfavorable compared to RFS in patients with NSMP 
tumors (HR=1.92, 1.20–3.07 CI, p=0.007) (Figure 3). Multivariable analysis was performed 
for Stage I only, demonstrating that patients with POLE mutant tumors had significantly 
longer RFS (p=0.05) (Supplemental Table 1A–B) (Figure 4). Following this multivariable 
analysis, p53abn remained prognostically unfavorable compared to NSMP, with respect to 
RFS (p=0.004).
Discussion
Bokhman’s subclassification of endometrial carcinomas into estrogen-driven type I and 
estrogen-independent type II tumors12 was a landmark achievement, and provided a 
framework for understanding most endometrial carcinomas. However, some of these 
neoplasms defied classification as type I or II, and the TCGA-based molecular classification 
offers both an improved system for subclassifcation and an explanation for the limitations of 
the type I versus II categorization. Particularly problematic are the 30% of endometrial 
carcinomas that are neither type I/low-grade endometrioid nor type II/serous, but are 
characterized by very high mutation burdens (with resulting neoantigen formation and 
prominent host immune response, as well as intratumoral morphological heterogeneity), i.e. 
MMRd and POLE subtypes.2 With regard to histotype, almost all copy number-low 
(NSMP), POLE mutant and MMRd tumors are endometrioid; although most of the copy 
number-high/p53abn tumors are serous, a significant minority are grade 3 EECs. Thus, 
grade 3 EECs are uniquely distributed amongst the four molecular subtypes, and our study 
confirms this. The outstanding question addressed herein was whether the molecular 
subtypes are of prognostic significance within the group of grade 3 EECs. In this group, 
stage remains an important prognostic factor with respect to both OS and RFS. POLE 
mutations are frequent, are associated with early stage disease, and arise in patients younger 
than those in other genomic subgroups. POLE mutant group assignment is independently 
associated with favorable OS and RFS, whereas p53abn is associated with a significantly 
worse prognosis.
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In addition to the fact that histotype assignment is suboptimally reproducible in high-grade 
EECs without molecular classification,13–16 the features reported as characteristic of each 
TCGA group are not sufficiently specific or reproducible to supplant the molecular 
classification itself. For example, dense tumor infiltrating lymphocytes and peritumoral 
lymphocytes are encountered in both the POLE mutant and MMRd groups.17–20 
Intratumoral heterogeneity may be seen in those groups as well as in the p53abn group, 
which contains an appreciable number of “mixed endometrioid and serous carcinomas”.2 
Additional reasons for pursuing molecular classification of FIGO grade 3 EECs include its 
potential usefulness in 1) Lynch Syndrome screening, 2) therapeutic prediction, and 3) 
differential diagnosis.
Classification as MMRd endometrioid carcinoma should trigger application of an algorithm 
that stratifies patients into two groups, each with a different likelihood of harboring germline 
abnormalities associated with Lynch Syndrome. The lowest-risk patients with MMRd 
carcinomas have tumors demonstrating abnormal MLH1 expression in the presence of 
MLH1 promoter methylation, or those with tumors harboring somatic MMR gene mutations, 
in the absence of germline mutations, in the same genes. Nearly all of the highest-risk 
patients have germline mutations in one of the DNA MMR genes or EPCAM; rarely, 
patients have “constitutive epimutation”, in which there is widespread methylation of the 
genome, including the MMR genes. The prognostic significance of a germline MMR 
mutation is currently unclear.
Ongoing interest in and success with immune checkpoint inhibitor therapy has encouraged 
the study of molecular phenotypes that are predictive of response to these agents. Although 
PD-1 blockade, for example, is not currently a first-line therapy for endometrial carcinoma 
patients, it has recently been FDA-approved for MMRd endometrial carcinomas in the 
setting of recurrence. The approval was based, in part, on the recognition that microsatellite 
unstable carcinomas, the vast majority of which are MMRd, are sensitive to immune 
checkpoint inhibition.21 MMRd FIGO grade 3 EECs are more likely than other genomic 
subgroups to present at an advanced stage, in which such therapy may be most applicable. 
This is based on the work of McMeekin,22 who reported heightened chemosensitivity and 
favorable prognosis for MMRd endometrial carcinomas treated with platinum-based agents. 
There are theoretical reasons to account for these responses in both MMRd and POLE 
mutant EECs. Deficient DNA repair results in at least a 100-fold increase in somatic 
mutations in tumor cell lines,23 resulting in the creation of “neo-antigens,” some of which 
may drive apoptosis and increase sensitivity to chemo- and radiotherapy. An immune-
mediated role is also suggested by the presence of rich tumor-infiltrating and peritumoral 
lymphocytes in these tumors.19 More recently, researchers have investigated the role of 
tumor-infiltrating lymphocytes in POLE-ultramutated tumors.24–26 Howitt et al showed that 
POLE-ultramutated endometrial carcinomas are associated with a high level of neoantigens 
and elevated CD8+ tumor-infiltrating lymphocytes, counterbalanced by overexpression of 
PDL-1 (an immune checkpoint); this suggests that such tumors might be excellent 
candidates for anti-PDL1 target therapies.24
Given that ~18% of grade 3 EECS and all serous carcinomas fall into the p53abn subgroup, 
we must ask whether it is necessary to rigorously distinguish these two subtypes of 
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endometrial cancer. A definitive answer is not obvious, although review of the demographic 
data reported herein reveals some potentially important differences, most notably the 
prevalence of Stage II–IV disease in serous carcinoma. In our cohort, only 20% of p53abn 
grade 3 EECs presented at a high stage. This stands in contrast to the 58% prevalence of 
surgically staged, high-stage endometrial serous carcinomas reported in the Memorial Sloan 
Kettering Cancer Center institutional database. It is possible that histotype and molecular 
profile provide different and potentially complementary information (which would support 
the practice of reporting both).
Although the NSMP (copy number-low) category of grade 3 EEC appeared homogeneous at 
first, review of the TCGA data disclosed heterogeneity, with probable clinical relevance. For 
example, amplification of chromosome 1q2,27 and mutations in exon3 of CTNNB1 (ß-
catenin)5,28,29 are prognostically unfavorable. Unfortunately, ß-catenin IHC is not a useful 
surrogate method for detecting prognostically unfavorable CTNNB1 exon 3 mutations. 
Going forward, the identification of these and other abnormalities may prove important, 
facilitating the stratification of tumors within this largest molecular subclass.
The proposed molecular integrated risk stratification will require sequencing of the 
exonuclease domain of POLE. Although there are commercially available POLE IHC 
antibodies, unpublished observations from several centers indicate that these cannot be 
applied to clinical practice at this time. It is possible that POLE antibodies with good 
performance characteristics, or surrogates thereof, could be developed. There may still be a 
role for assessing histological features that are likely to be encountered in POLE mutant 
tumors, such as obvious peritumoral and tumor-infiltrating lymphocytes.30 When 
endometrial cancers with pronounced TILS are found to be DNA MMR-proficient, the 
likelihood of POLE mutant subgroup assignment increases. There may also be 
circumstances in which more costly sequencing could be avoided; for example, in advanced 
stage tumors, in which the likelihood of POLE mutations is extremely small. Additional 
study is needed to determine how POLE status impacts triage for surgical staging and 
treatment. If POLE mutation is identified in a biopsy, can lymph node dissection be 
avoided? Is adjuvant chemo- or radiotherapy beneficial in the setting of a grade 3 deeply 
invasive POLE-mutant tumor? Would the excellent prognosis, observed in this and prior 
studies, be possible without additional treatment? Only with this information can the role 
and timing of POLE mutational analysis be defined. The increasing use of next-generation 
sequencing platforms that recognize hundreds of somatic mutations simultaneously, 
including the exonuclease domains of POLE, is likely to supplant Sanger sequencing or IHC 
in detecting such mutations. It is encouraging that next-generation sequencing platforms 
including the DNA mismatch repair genes, and assessment of microsatellite instability, are 
now FDA-approved, and should [theoretically] be reimbursable by insurance companies.
The current study included patients with grade 3 EECs of all stages, irrespective of adjuvant 
treatment given. This resulted in a large but clinically heterogeneous retrospective study 
cohort. Therefore, we cannot make any definitive conclusions with respect to the putative 
effect of adjuvant treatment on the TCGA subclasses. Molecular analysis of a study cohort 
from a randomized controlled trial, such as PORTEC-3, will be of interest in exploring the 
effects of adding chemotherapy to the treatment regimen. Another potential limitation of our 
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study is the fact that there were some minor differences in methodology between the 
participating centers, and not all cases were centrally reviewed. POLE testing was performed 
by NGS covering exon 9–14 by some centers; others limited their analysis to exon 9 and 13 
by Sanger sequencing. It remains to be seen which methods will emerge as the standard in 
clinical practice. As molecular subclassification enters clinical practice, it will be necessary 
to develop appropriate proficiency testing programs to ensure that the quality of biomarker 
testing meets the expected standards (e.g. the ASCO-CAP guidelines for breast cancer 
biomarker assessment). However, the technical differences between participating 
laboratories are unlikely to have had any major impact on our results and conclusions. 
Unlike the TCGA study, the current study utilized techniques that are widely available and 
commonly used in clinical practice. Our study population included a well-annotated cohort 
of 381 patients with FIGO grade 3 EECs, with a median follow-up of almost 7 years.
In summary, we have shown that the pathologic entity typically recognized as “FIGO grade 
3 endometrioid carcinoma” is, in reality, a collection of at least four distinct disease types. In 
this era of increasingly individualized patient care, the elucidation and recognition of these 
subgroups will contribute significantly to prognostication and the selection of novel 
therapeutics.
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Use of immunohistochemistry for molecular subgroup assignment (A) FIGO grade 3 
endometrioid carcinoma with p53 overexpression (p53abn subgroup). (B) FIGO grade 3 
endometrioid carcinoma with loss of MLH1 expression (MMRd subgroup). (C) FIGO grade 
3 endometrioid carcinoma with normal expression p53 staining, no DNA MMR 
abnormalities (not shown) and no POLE hotspot mutation (NSMP subgroup). (D) FIGO 
grade 3 endometrioid carcinoma lacking immunohistochemical abnormalities. POLE hotspot 
mutation identified (POLE subgroup).
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FIGO stage is associated with recurrence-free survival.
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Molecular subgroup is associated with overall (A) and recurrence-free survival (B) in FIGO 
grade 3 endometrioid carcinoma.
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Molecular subgroup is associated with overall (A) and recurrence-free survival (B) in FIGO 
stage I, grade 3 endometrioid carcinoma.
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